Status:
COMPLETED
Virtual Reality Intervention Alleviates Dyspnea in Patients Recovering From COVID Pneumonia
Lead Sponsor:
Ecole Polytechnique Fédérale de Lausanne
Collaborating Sponsors:
Mindmaze SA
Conditions:
Covid19
Dyspnea
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The present COVID-19 Virtual Reality (COVVR) clinical study is performed to test the hypothesis that an immersive virtual reality (iVR)-based Digital Therapeutics (DTx), would alleviate dyspnea by imp...
Detailed Description
Persistent dyspnea is the experience of breathlessness that persists despite optimal treatment of the underlying pathophysiology, and results in physical, psychosocial disability for the patient. As o...
Eligibility Criteria
Inclusion
- Recovering from COVID-19 pneumonia confirmed by RT-PCR for SARS-CoV-2
- Presented with persistent dyspnea with a self-rated intensity of five or higher (out of ten) on a visual analog dyspnea scale. ( "Do you have difficulty breathing?" "On a scale of 0 to 10, with 0 being no difficulty to breathe and 10 being the worst difficulty to breathe that you can imagine, where do you rank?".) This dyspnea rating will only used as an inclusion criterion and not as an outcome.
- Being able to give consent
- Being able to understand and speak French or English
Exclusion
- Any unstable respiratory, neurological, and cardiac conditions
- Any psychiatric illness
- Montreal Cognitive Assessment (MoCA) score below 25.
Key Trial Info
Start Date :
November 26 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 6 2021
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04844567
Start Date
November 26 2020
End Date
April 6 2021
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopitaux Universitaires de Geneve (HUG)
Geneva, Switzerland, 1205